Oligodendrocytes are the cells that make myelin in the brain and spinal cord. They develop from oligodendrocyte progenitor cells (OPCs), and researchers follow that development with marker proteins that appear and disappear at each stage: PDGFRA and NG2 on progenitors, O4 and O1 as cells start to differentiate, and myelin proteins such as MBP, PLP, MAG and MOG in mature cells, with the transcription factors OLIG2 and SOX10 present throughout.[1] The same markers are used to study how myelin is repaired, or fails to be repaired, in diseases such as multiple sclerosis.
Myelin is an extension of the oligodendrocyte’s own membrane, wrapped tightly around an axon.[1] It insulates the nerve fibre and lets the electrical impulse jump from one gap in the myelin to the next, which makes conduction much faster. In autoimmune diseases such as multiple sclerosis, the immune system damages myelin, exposing the nerve fibre underneath and slowing or blocking its signals.[2]
How Myelination Works
Oligodendrocyte progenitor cells arise in the ventricular zones of the developing brain and spinal cord, the layer where neural stem cells sit, and migrate throughout the central nervous system before maturing into myelinating oligodendrocytes.[3] Each oligodendrocyte sends out several processes, and each process wraps a segment of an axon, so one cell myelinates several axon segments, on one axon or on different ones.[4] OPCs do not disappear once the brain is built. They remain throughout the adult central nervous system, where, in rodents, they keep dividing and producing new oligodendrocytes at a declining rate and respond to injury by dividing faster. Adult OPCs also form synapses with unmyelinated axons and respond to their electrical activity by making more oligodendrocytes and myelin locally, a form of adaptive myelination involved in some kinds of learning, such as motor learning.[3]
The markers below are the ones most often used to tell these stages apart. None is perfect on its own, so studies combine a lineage marker such as OLIG2 or SOX10 with a stage marker.[1]
| Stage | Markers | What they are and what they show |
|---|---|---|
| Whole lineage, every stage | OLIG2, OLIG1, SOX10 | Transcription factors present throughout the oligodendrocyte lineage. In animal studies, OLIG2 is essential for neural progenitors to become OPCs, and SOX10 for lineage specification and OPC differentiation.[1] |
| Oligodendrocyte progenitor cell (OPC) | PDGFRA (PDGFR-alpha), NG2 (CSPG4), A2B5 | PDGFRA is the best-characterized OPC marker: the receptor for PDGF-A, the most potent signal driving OPCs to divide and survive. NG2 is a surface proteoglycan of early lineage cells; in animal studies, NG2-positive cells can also become astrocytes. A2B5 is an antibody that labels committed early cells.[1] |
| Late progenitor to pre-myelinating oligodendrocyte | O4, O1 (galactocerebroside, GalC), CNPase | O4 appears already in late progenitors, while O1 is typical of pre-myelinating oligodendrocytes, which start to extend membrane but have not yet wrapped axons. CNPase is present at this stage and in myelinating cells.[1] The O1 antibody recognizes galactocerebroside (GalC), a myelin lipid. In rat brain cultures, O4-positive progenitors appear before galactocerebroside and sulfatide are expressed, and sulfatide synthesis first appears in O1-positive cells[5]; GalC then remains in mature, myelinating cells.[1] |
| Mature, myelinating oligodendrocyte | MBP, PLP, MAG, MOG, with GalC persisting (and OLIG2) | Proteins and lipids of the myelin sheath. MBP sits on the inner face of the membrane and PLP, the most abundant myelin protein, spans it; in mice, MBP and MAG first appear around postnatal days 5 to 7 and MOG one to two days later.[1] |
Two details often cause confusion. PLP is not only a mature marker: its smaller form DM-20 is already made by newborn OPCs. And the transcription factor Nkx2.2 regulates the timing of differentiation rather than marking one stage.[1]
Mechanisms of Myelination
Once an oligodendrocyte has matured, its processes find axons, wrap them in many layers of lipid-rich membrane and compact the layers into the myelin sheath, leaving short gaps, the nodes of Ranvier, between segments. Which axons are myelinated, and how thickly, depends partly on the axons themselves: in rodents, electrical activity in an axon prompts OPCs nearby to make more oligodendrocytes and myelin.[3] Inside the cell, transcription factors such as OLIG1, OLIG2, SOX10 and Nkx2.2 control when differentiation and myelination happen.[1]
In the adult human brain, the oligodendrocytes themselves are remarkably stable. Carbon dating of their DNA showed that the number of oligodendrocytes in the corpus callosum is set in childhood, and that only about 1 in 300 white-matter oligodendrocytes is replaced each year, while the myelin they make is exchanged at a high rate. Adjusting myelin in adults therefore seems to fall mainly to existing oligodendrocytes rather than new ones.[6]
Remyelination and Multiple Sclerosis
After myelin is lost, the central nervous system can rebuild it. Remyelination follows a set sequence: OPCs near the damage are activated, migrate into it, multiply and differentiate into new myelinating oligodendrocytes.[7] In multiple sclerosis, this repair often fails. In a study of 48 chronic lesions taken at autopsy from 10 patients, 34 contained oligodendrocytes whose processes had reached demyelinated axons but had not myelinated them, and in places these pre-myelinating cells were as dense as in the developing brain. The authors concluded that, in these lesions, remyelination was limited not by a lack of progenitors but by axons that were no longer receptive.[8]
Findings like this led to drugs meant to help progenitors mature and myelinate. Published results, led by the largest trial:
| Drug and trial | Design and size | Result |
|---|---|---|
| Opicinumab, an antibody against the differentiation blocker LINGO-1 (SYNERGY) | Phase 2, randomized, placebo-controlled, dose-ranging; 419 patients with relapsing MS, 72 weeks | Primary endpoint not met: confirmed disability improvement in 49% with placebo and 40% to 65% across doses, with no dose-response trend (p = 0.89).[9] |
| Bexarotene, a retinoid X receptor agonist (CCMR One) | Phase 2a, randomized, placebo-controlled; 52 patients with relapsing-remitting MS, 6 months | No difference on the primary MRI measure of remyelination; every patient on bexarotene had side effects, including central hypothyroidism in all 26. The investigators advised against its use in MS.[10] |
| Clemastine, an antihistamine (ReBUILD) | Randomized, placebo-controlled, double-blind crossover; 50 patients with relapsing MS and chronic optic nerve damage | The delay of the visual evoked potential, a measure of conduction in the optic nerve, shortened by 1.7 milliseconds per eye; fatigue, no serious adverse events.[11] |
| Clemastine (TRAP-MS platform trial) | Added arm in patients with progressive MS | Stopped when 3 of 9 patients met safety stopping criteria; disability progressed faster on clemastine than in the other trial participants, linked to a form of inflammatory cell death (pyroptosis).[12] |
None of these trials has shown that a remyelinating drug improves disability. Clemastine is the only one with a positive randomized result, on a measure of nerve conduction rather than on disability, and it appeared harmful in progressive MS.
Transplanting Myelinating Cells
The other approach is to supply new myelinating cells. In shiverer mice, which cannot make compact myelin and die by 18 to 21 weeks of age, human glial progenitor cells transplanted at birth myelinated the whole brain and spinal cord and rescued a significant fraction of the animals, which lived far longer.[13] In people, trials have been small and uncontrolled:
- Pelizaeus-Merzbacher disease, an inherited disorder in which oligodendrocytes cannot myelinate because of a PLP1 mutation: in a phase 1 study, four male patients with an early-onset severe form received donor human neural stem cells (HuCNS-SC) into frontal white matter, with 9 months of immunosuppression. The procedure was well tolerated, three showed modest neurological gains, and MRI changes at the transplant sites were consistent with new myelin.[14]
- Spinal cord injury: in an open-label phase 1/2a study, 25 people with subacute cervical injuries received a single dose of OPCs made from human pluripotent stem cells (LCTOPC1, formerly AST-OPC1) injected into the cord at the injury site.[15] MRI showed no masses or cord damage from the injections. There were 29 serious adverse events, two of them judged related to the injection procedure or to immunosuppression (a leak of spinal fluid and a bacterial infection), and at one year 21 of 22 participants had recovered one or more neurological levels on at least one side. The study had no control group, so it cannot show how much of that recovery the cells caused.[16]
Both studies were small, and neither was in multiple sclerosis. How these cells fit among the other cells of the nervous system is covered on our page on neural stem cells and glial cells, and how myelin speeds nerve signals on our page on neurons and neurotransmitters.
Published Clinical Citations
[1] ^ Kuhn S, Gritti L, Crooks D, Dombrowski Y. Oligodendrocytes in development, myelin generation and beyond. Cells. 2019;8(11):1424. https://doi.org/10.3390/cells8111424
[2] ^ Clark MA, Douglas M, Choi J. Biology 2e. Section 35.2, How Neurons Communicate. OpenStax, Rice University; 2018. https://openstax.org/books/biology-2e/pages/35-2-how-neurons-communicate
[3] ^ Bergles DE, Richardson WD. Oligodendrocyte development and plasticity. Cold Spring Harbor Perspectives in Biology. 2015;8(2):a020453. https://doi.org/10.1101/cshperspect.a020453
[4] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 12.2, Nervous Tissue. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/12-2-nervous-tissue
[5] ^ Bansal R, Warrington AE, Gard AL, Ranscht B, Pfeiffer SE. Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb used in the analysis of oligodendrocyte development. Journal of Neuroscience Research. 1989;24(4):548-557. https://doi.org/10.1002/jnr.490240413
[6] ^ Yeung MS, Zdunek S, Bergmann O, et al. Dynamics of oligodendrocyte generation and myelination in the human brain. Cell. 2014;159(4):766-774. https://doi.org/10.1016/j.cell.2014.10.011
[7] ^ Franklin RJM, ffrench-Constant C. Regenerating CNS myelin: from mechanisms to experimental medicines. Nature Reviews Neuroscience. 2017;18(12):753-769. https://doi.org/10.1038/nrn.2017.136
[8] ^ Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. New England Journal of Medicine. 2002;346(3):165-173. https://doi.org/10.1056/NEJMoa010994
[9] ^ Cadavid D, Mellion M, Hupperts R, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology. 2019;18(9):845-856. https://doi.org/10.1016/S1474-4422(19)30137-1
[10] ^ Brown JWL, Cunniffe NG, Prados F, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurology. 2021;20(9):709-720. https://doi.org/10.1016/S1474-4422(21)00179-4
[11] ^ Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390(10111):2481-2489. https://doi.org/10.1016/S0140-6736(17)32346-2
[12] ^ Kocot J, Kosa P, Ashida S, et al. Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis. Journal of Clinical Investigation. 2025;135(10):e183941. https://doi.org/10.1172/JCI183941
[13] ^ Windrem MS, Schanz SJ, Guo M, et al. Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell. 2008;2(6):553-565. https://doi.org/10.1016/j.stem.2008.03.020
[14] ^ Gupta N, Henry RG, Strober J, et al. Neural stem cell engraftment and myelination in the human brain. Science Translational Medicine. 2012;4(155):155ra137. https://doi.org/10.1126/scitranslmed.3004373
[15] ^ McKenna SL, Ehsanian R, Liu CY, et al. Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury. Journal of Neurosurgery: Spine. 2022;37(3):321-330. https://doi.org/10.3171/2021.12.SPINE21622
[16] ^ Fessler RG, Ehsanian R, Liu CY, et al. A phase 1/2a dose-escalation study of oligodendrocyte progenitor cells in individuals with subacute cervical spinal cord injury. Journal of Neurosurgery: Spine. 2022;37(6):812-820. https://doi.org/10.3171/2022.5.SPINE22167